GT
CSTL icon

Glenmede Trust’s Castle Biosciences CSTL Stock Holding History

Glenmede Trust’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$204K Buy
8,536
+368
+5% +$8.2K ﹤0.01% 1339
2026
Q1 		$201K Sell
8,168
-22
-0.3% -$721 ﹤0.01% 1315
2025
Q4 		$319K Buy
+8,190
New +$264K ﹤0.01% 1114

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Glenmede Trust's CSTL Position: Q2 2026 in Review

Glenmede Trust increased its Castle Biosciences (CSTL) stake by 4.5% in Q2 2026, buying an estimated $8.2K and bringing the position to 8,536 shares worth $204K. The position accounts for ﹤0.01% of the portfolio, ranked #1339.

Glenmede Trust first reported a position in CSTL in Q4 2025 and has held it in 3 quarters since. The position peaked at $319K in Q4 2025. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Glenmede Trust held 8,536 shares of Castle Biosciences worth $204K as of Q2 2026.
  • Glenmede Trust bought 368 Castle Biosciences shares in Q2 2026, an estimated $8.2K.
  • Castle Biosciences made up ﹤0.01% of Glenmede Trust's portfolio in Q2 2026, its #1339 holding.
  • Glenmede Trust first reported a position in Castle Biosciences in Q4 2025 and has held it in 3 quarters since.
  • Glenmede Trust's Castle Biosciences position peaked at $319K in Q4 2025.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Glenmede Trust's 13F filing for Q2 2026, filed 10 Aug 2026.